Are We Valuing Prescription Drugs Appropriately?
That is the title of a new Health Affairs Forefront article by Peter Neumann and Joshua Cohen. An excerpt is below: One reason economic analyses may yield estimates that are too low is that they ignore the downstream declines in drug prices that occur when competitors enter the market and especially with the introduction of…